Pros | Among most bought funds within the category. Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | 3Y returns in the top 25% of the category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 6/8 | 4/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 11 Years | 11 Years | ||
Fund Size | 7125 Cr | 2626 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.92% | 0.95% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | S&P BSE Healthcare PR | S&P BSE Healthcare PR |
No of Holdings | 35 | 28 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (14.91%) Lupin Ltd (8.4%) Cipla Ltd (6.51%) Apollo Hospitals Enterprise Ltd (5.79%) Dr Reddy's Laboratories Ltd (4.75%) | Sun Pharmaceuticals Industries Ltd (14.81%) Cipla Ltd (7.52%) Max Healthcare Institute Ltd Ordinary Shares (6.87%) Mankind Pharma Ltd (5.26%) Lonza Group Ltd ADR (4.75%) | ||
No of Sectors | 3 | 3 | ||
Top 3 Sectors | Health (97.16%) Corporate (0.31%) Government (0.14%) | Health (94.47%) Basic Materials (4.16%) Corporate (0.23%) | ||
Equity % | 97.16% | 98.63% | ||
Debt % | - | - | ||
P/E | 40.73 | 45.64 | ||
P/B | 6.18 | 6.13 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -0.18% | 0.29% | ||
3-Month Return | 3.2% | 6.56% | ||
6-Month Return | 24.76% | 28.01% | ||
1-Year Return | 53.63% | 55.4% | ||
3-Year Return | 16.67% | 18.76% | ||
5-Year Return | 24.42% | 25.02% |
Sharpe | 0.78 | 0.93 | ||
Alpha | 1.7 | 3.99 | ||
Beta | 0.95 | 0.89 | ||
Standard Deviation | 14.61 | 14.04 | ||
Information Ratio | 0.58 | 0.91 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Kinjal Desai,Sailesh Raj Bhan | Tanmaya Desai,Mohit Jain |